Hematology. American Society of Hematology. Education ProgramHumansIsocitrate Dehydrogenasefms-Like Tyrosine Kinase 3LeukemiaMyeloid
Targeted triplet therapies incorporating FLT3 or IDH inhibitors: ready for prime time?
Himachandana Atluri, Yasmin Abaza, Jessica K Altman
Published: 202510.1182/hematology.2025000754
Abstract
Combination therapies in acute myeloid leukemia (AML) are an area of current investigation due to the potential of overcoming resistance by targeting multiple pathways simultaneously. Triplet therapies combining hypomethylating agents, venetoclax, an…
Preview only. Read the full abstract at the source